
Bayer Seeks U.S. Approval for Gadoquatrane
Bayer Submits New Drug Application for Gadoquatrane, a Next-Generation MRI Contrast Agent with Significantly Reduced Gadolinium Dose Bayer, a global leader in life sciences and healthcare innovation, announced today the submission of a New Drug Application (NDA) to the U.S.…












